| abstract |
The present invention provides a pharmaceutical formulation for use in the administration of 2 (1H) -quinolinone derivative long acting β 2 -agonists by inhalation. A chemically stable highly effective TA2005HFA solution formulation administered by a pressurized metered dose inhaler (pMDI) characterized by deep lung penetration is a fraction of particles less than or equal to 1.1 μm. Is 30% or more, preferably 50% or more. Also the process for producing the formulation and its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). [Selection figure] None |